Literature DB >> 17056129

Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.

Hai Yan Zhang1, Xi Can Tang.   

Abstract

In recent years, the most common pharmacological treatment for Alzheimer's disease (AD) has been acetylcholinesterase (AChE) inhibition. However, this single-target approach has limited effectiveness and there is evidence that a multitarget approach might be more effective. Huperzine A (HupA), a novel alkaloid isolated from a Chinese herb, has neuroprotective effects that go beyond the inhibition of AChE. Recent data have demonstrated that HupA can ameliorate the learning and memory deficiency in animal models and AD patients. Its potentially beneficial actions include modification of beta-amyloid peptide processing, reduction of oxidative stress, neuronal protection against apoptosis, and regulation of the expression and secretion of nerve growth factor (NGF) and NGF signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056129     DOI: 10.1016/j.tips.2006.10.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  41 in total

Review 1.  Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia.

Authors:  Ying Wang; Lu-qi Huang; Xi-can Tang; Hai-yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

2.  Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model.

Authors:  Chun-Yan Wang; Wei Zheng; Tao Wang; Jing-Wei Xie; Si-Ling Wang; Bao-Lu Zhao; Wei-Ping Teng; Zhan-You Wang
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

3.  Studies of natural products on treating neurological disorders in China.

Authors:  Hai Yan Zhang; Xi Can Tang
Journal:  Cell Mol Neurobiol       Date:  2007-11-28       Impact factor: 5.046

Review 4.  Huperzine A for vascular dementia.

Authors:  Zilong Hao; Ming Liu; Zhiqin Liu; Donghao Lv
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

5.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

Review 6.  Huperzine A for mild cognitive impairment.

Authors:  Jirong Yue; Bi Rong Dong; Xiufang Lin; Ming Yang; Hong Mei Wu; Taixiang Wu
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

7.  Inhibiting β-amyloid-associated Alzheimer's pathogenesis in vitro and in vivo by a multifunctional dimeric bis(12)-hupyridone derived from its natural analogue.

Authors:  Shengquan Hu; Rui Wang; Wei Cui; Zaijun Zhang; Shinghung Mak; Daping Xu; Chunglit Choi; Karl Wahkeung Tsim; Paul R Carlier; Mingyuen Lee; Yifan Han
Journal:  J Mol Neurosci       Date:  2014-11-19       Impact factor: 3.444

8.  Huperzine A derivative M3 protects PC12 cells against sodium nitroprusside-induced apoptosis.

Authors:  Na Ning; Jin-feng Hu; Yu-he Yuan; Xin-yuan Zhang; Jun-gui Dai; Nai-hong Chen
Journal:  Acta Pharmacol Sin       Date:  2011-11-28       Impact factor: 6.150

9.  [+]-Huperzine A protects against soman toxicity in guinea pigs.

Authors:  Ying Wang; Yanling Wei; Samuel Oguntayo; Neil Jensen; Bhupendra P Doctor; Madhusoodana P Nambiar
Journal:  Neurochem Res       Date:  2011-08-07       Impact factor: 3.996

10.  Timosaponin B-II ameliorates scopolamine-induced cognition deficits by attenuating acetylcholinesterase activity and brain oxidative damage in mice.

Authors:  Xu Zhao; Chunmei Liu; Yu Qi; Lina Fang; Jie Luo; Kaishun Bi; Ying Jia
Journal:  Metab Brain Dis       Date:  2016-07-22       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.